SUTUDIES ON THE RELATIONSHIP BETWEEN EPIDERMAL GROWTH FACTOR FAMILY EXPRESSION AND CARCINIGENESIS AND PROGESSION OF HEPATODELLULAR CRACINOMA : A SPECIAL REFERENCE TO HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR EXPRESSION

表皮生长因子家族表达与肝细胞癌癌变和进展关系的研究:肝素结合表皮生长因子样生长因子表达的特殊参考

基本信息

  • 批准号:
    09670242
  • 负责人:
  • 金额:
    $ 1.86万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    1997
  • 资助国家:
    日本
  • 起止时间:
    1997 至 1999
  • 项目状态:
    已结题

项目摘要

HB-EGF expression was comparatively investigated in human hepatocellular carcinoma (HCC) and non-HCC tissues by using immunohistochemical technique. Both of hepatocytes and HCC cells expressed heparin binding -growth factor-like growth factor (HB-EGF) in the cytoplasm. Since HB-EGF positive rate and staining intensity tended to increase after neoplastic transformation of hepatocytes, and since the staining intensity tended to increase along with the histologic grade of HCC, a possible role of HB-EGF in the development and progression of HCC would be suggested. Sarcomatous HCCs tended to show more intensive immunostaining in the sarcomatous components than in the HCC components. HB-EGF expression was also noted in macrophages, fibroblasts, and endothelial cells in the cancerous and noncancerous sinusoids. These results suggest that HCC dells may possess a proliferation mechanism regulated by an autocrine and a paracrine mechanisms which are mediated by HB-EGF and epidermal growth factor … More (EGF) receptor. HCC cell line experiments revealed that HCC cells frequently express transforming growth factor (TGF)-α, but rarely express HB-EGF. HCC cells may possess a paracrine system regulated not only by HB-EGF, but also by TGF-α, EGF, and amphiregulin ; and an autocrine growth mechanism regulated by an unknown EGF family member and EGFR, one regulated by TGF-α and EGFR under a certain condition. Expression of CD9, which enhances a juxtacrine growth mechanism regulated by HB-EGF and EGF receptor, was observed in hepatocytes, and sinusoidal lining cells in HCC and nonHCC tissues. CD9 expression was more frequently observed in well-differentiated HCC tissues than in moderately differentiated HCC tissues. In conclusion, it was suggested that HB-EGF expression may relate with hepatocarcinogenesis and HCC progression, and that the proliferation of well differentiated HCCs may be regulated not only by a paracrine and/or an autocrine mechanisms mediated by HB-EGF, but also by a juxtacrine mechanism mediated by HB=EGF in cooperation with CD9. Less
应用免疫组化技术比较研究HB-EGF在人肝细胞癌(HCC)和非HCC组织中的表达。肝细胞和HCC细胞细胞质中均表达肝素结合生长因子样生长因子(HB-EGF)。由于HB-EGF的阳性率和染色强度在肝细胞瘤化转化后呈增加趋势,且染色强度随HCC的组织学分级呈增加趋势,提示HB-EGF可能在HCC的发生发展中起作用。肉瘤性HCC的免疫染色倾向于在肉瘤成分中比在HCC成分中表现出更强的强度。在癌变和非癌变鼻窦的巨噬细胞、成纤维细胞和内皮细胞中也发现HB-EGF的表达。这些结果提示HCC细胞可能具有由HB-EGF和表皮生长因子(EGF)受体介导的自分泌和旁分泌机制调节的增殖机制。HCC细胞系实验显示,HCC细胞频繁表达转化生长因子(TGF)-α,但很少表达HB-EGF。HCC细胞可能具有旁分泌系统,不仅受HB-EGF的调节,还受TGF-α、EGF和双调节蛋白的调节;一种是由未知的EGF家族成员和EGFR调控的自分泌生长机制,一种在一定条件下由TGF-α和EGFR调控。CD9的表达增强了由HB-EGF和EGF受体调控的近肽生长机制,在HCC和非HCC组织的肝细胞和窦壁细胞中均有表达。CD9在高分化HCC组织中的表达高于中分化HCC组织。综上所述,HB-EGF的表达可能与肝癌的发生和HCC的进展有关,高分化HCC的增殖可能不仅受到HB-EGF介导的旁分泌和/或自分泌机制的调节,还可能受到HB=EGF与CD9协同介导的近分泌机制的调节。少

项目成果

期刊论文数量(15)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Haramaki M, Yano H. et al.: "CD9 reduces xenotransplantability of human hepatoma cells into nude mice"Hepatology. 28(4)-2. 513A (1998)
Haramaki M、Yano H. 等人:“CD9 降低了人肝癌细胞向裸鼠的异种移植性”肝病学。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Higaki K., Yano H. et al: "Expression of heparin-binding epidermal growth factor-like growth factor in hepatocellular carcinoma and noncancerous tissues"Hepatology. 30 (4) pt 2. 260A (1999)
Higaki K.,Yano H.等人:“肝素结合表皮生长因子样生长因子在肝细胞癌和非癌组织中的表达”肝病学。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Hisaka T., Yano H. et al: "Expressions of epidermal growth factor family and its receptor in human hepatocelllular carcinoma lines : Relationship to cell proliferation"Int J Oncol. 14. 453-460 (1999)
Hisaka T.,Yano H.等人:“表皮生长因子家族及其受体在人肝细胞癌细胞系中的表达:与细胞增殖的关系”Int J Oncol。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Haramaki M., Yano H. et al: "CD9 reduces xenotransplantability of human hepatoma cells into nude mice"Hepatology. 28 (4) pt. 2. 513A (1998)
Haramaki M.、Yano H. 等人:“CD9 降低了人肝癌细胞向裸鼠的异种移植性”肝病学。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Hisaka T,Yano H,et al.: "Expressions of epidermal growth factor family and its receptor in human hepatocellular carcinoma cell lines: Relationship to cell proliferation." Intemational Journal of Oncology. 14. 453-460 (1999)
Hisaka T,Yano H,et al.:“表皮生长因子家族及其受体在人肝细胞癌细胞系中的表达:与细胞增殖的关系。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

YANO Hirohisa其他文献

YANO Hirohisa的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('YANO Hirohisa', 18)}}的其他基金

Identification of diagnostic marker of combined hepatocellular-cholangiocarcinoma subtypes by gene expression analysis
通过基因表达分析鉴定肝细胞胆管癌联合亚型的诊断标志物
  • 批准号:
    18K07032
  • 财政年份:
    2018
  • 资助金额:
    $ 1.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Basic studies on the treatment and prevention of hepatocellular carcinoma with interferon
干扰素治疗和预防肝细胞癌的基础研究
  • 批准号:
    19590412
  • 财政年份:
    2007
  • 资助金额:
    $ 1.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Basic research on anti-tumor effects of Interferon-α on hepatocellular carcinoma
干扰素-α抗肝癌作用的基础研究
  • 批准号:
    13670233
  • 财政年份:
    2001
  • 资助金额:
    $ 1.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了